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Clindamycin is an antibiotic effective against Gram-positive aerobes and both Gram-
negative and Gram-positive anaerobic pathogens. Clindamycin (its phosphate ester) was us-
ed as a model drug for our study in order to check the efficacy of the developed vaginal gel 
formulations.  
The aim of this study was to develop an analytical method suitable for the determina-
tion of clindamycin phosphate in three different vaginal gel formulations. The main difference 
between the three formulations was the use of different gelation agents in the formulations 
(Carbopol® 940, Carbopol® Ultrez 10 and Pemulen® TR 1). A new isocratic high performance 
liquid chromatography method based on reverse phase separation has been developed for 
the determination of clindamycin phosphate. The separation was achieved on a Zorbax Ecli-
pse plus C8 column with a mobile phase of acetonitrile and pH 2.5 phosphate buffer and UV 
detection at 210 nm. A linear response (r>0.99) was observed in the range of 10.0-80.0 μg 
mL-1. The method shows good recoveries and relative standard deviations were less than 
1.0%. The method can be applied to assess the stability of clindamycin phosphate in vaginal 
gel formulations. It can be used for quality control and stability study samples analysis. 
Clindamycin phosphate concentration was different in vaginal gel formulations with dif-
ferent gelation agents, so the conclusion is that gelation agents (gel carriers) have a signi-
ficant influence on the active drug concentration. The obtained results confirm that vaginal 
gel formulation with Carbopol® 940 shows the maximal stability during the analysis and 
provides the optimal value of clindamycin phosphate concentration. 
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Clindamycin is an antibiotic effective against 
Gram-positive aerobes and both Gram-negative and 
Gram-positive anaerobic pathogens. It is synthesized by 
chemical modification of lincomycin, an antibiotic pro-
duced by microbial fermentation Streptomyces lincolne-
nsis, to increase the biological activity (1). Chemically, 
both antibiotics are weak bases. Clindamycin has grea-
ter antibacterial power and is better absorbed than lin-
comycin orally. Structures of clindamycin and related 
compounds are shown in Figure 1. 
 
 
Figure 1.  Structures of clindamycin and related 
compounds 
 
Clindamycin inhibits bacterial protein synthesis at 
the level of the bacterial ribosome. The effect of clin-
damycin, which is primarily bacteriostatic, is exerted by 
its binding to the 50S ribosomal subunit and affects the 
process of peptide chain initiation (2, 3). 
Clindamycin can be found as clindamycin hydro-
chloride, clindamycin palmitate (used in pediatrics) and 
clindamycin phosphate (used intramuscularly, intrave-
nously, topically). It can be applied orally (hydrochloride 
and palmitate), parenterally (phosphate) and locally in 
the treatment of vaginal infections and acne (hydro-
chloride, phosphate) (4). 
Some clinical trials confirmed that clindamycin 
is very effective in treating vaginal bacterial diseases. 
The frequency of adverse effects on the digestive sys-
tem after the application of clindamycin phosphate va-
ginal gel is very low (5). The local (vaginal) treatment 
of clindamycin phosphate has a clear advantage over 
the systemic one. Treatment is carried out by direct 
acting on the cause of the infection (6, 7). 
Clindamycin is indicated for the treatment of 
bacterial vaginosis (formerly referred to as Haemophi-
lus vaginitis, Gardnerella vaginitis, non-specific vagini-
tis, Corynebacterium vaginitis or anaerobic vaginosis) in 
non-pregnant women (2). Clindamycin was used as a 
model drug for our present study in order to check the 
efficacy of the developed vaginal gel formulations. 
Its phosphate ester is produced by chemical mo-
dification of clindamycin (8). Although the ester is not 
biologically active, the prodrug clindamycin 2-phosphate 
is rapidly converted in vivo to the parent drug, clindamy-
cin, by phosphatase ester hydrolysis. Clindamycin phos-
phate, unlike clindamycin, is highly water-soluble and 
does not produce pain upon injection. Aqueous soluti-
ons of clindamycin 2-phosphate show a maximum sta-
bility at pH 3.5-6.5 (5). 
Clindamycin phosphate can be determined us-
ing reverse phase chromatography with low wavelength 
detection along with aqueous acetonitrile or methanol 
mixtures (5). Several methods have been established 
for the determination of clindamycin in bulk drugs and 
formulations. Microbiological and spectrophotometric 
assays suffer from both the lack of specificity and 
accuracy. Gas-liquid chromatography (GLC) compen-
sates for the previous, but requires a relatively compli-
cated sample manipulation. High performance liquid 
chromatography (HPLC) methods are much more accu-
rate and precise. Refractive index, electrochemical and 
UV detection have been applied. UV detection seems to 
offer more, in terms of sensitivity and stability (3, 9, 10). 
Also, HPLC analytical method for the determina-
tion of clindamycin in human plasma and oral solutions 
has been developed (10, 11). 
However, to our knowledge, there are no reports 
in the literature regarding any analytical method that is 
able to analyse this drug with UV absorbing characte-
ristics in vaginal gel formulations.  
The aim of this study was to develop an analyti-
cal method suitable for the determination of clindamy-
cin phosphate in three different vaginal gel formulati-
ons. 
The main difference between formulations was 
the use of different gelation agents in the formulations 
(Carbopol® 940, Carbopol® Ultrez 10 and Pemulen® TR 
1). All agents (polymers) show similar organoleptic pro-
perties and satisfactory viscosity parameters as vaginal 
gel carriers and their formulations meet the require-
ments of the European Pharmacopoeia (12).  
In order to assess the chemical stability of the 
clindamycin phosphate in these vaginal gel formulati-
ons, development of stability - indicating analytical me-
thod is needed. 
 
MATERIALS AND METHODS 
 
Chemica ls  and reagents  
 
Carbopol® 940 (2-propenoic acid homopolymer 
or poly(acrylic acid)), Carbopol® Ultrez 10 (a cross-linked 
poly(acrylic acid)) and Pemulen® TR 1 (2-methylbuta-
noic acid homopolymer) were purchased from Noveon 
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(USA). Propylenglycol and concentrated phosphoric acid 
were the European Pharmacopoeia 6.0 chemical refe-
rence substances. Disodium edetate and sodium dihy-
drogen phosphate were also the European Pharmaco-
poeia 6.0 chemical reference substances. HPLC grade 
acetonitrile was purchased from Merck (USA). Sodium 
hydroxide solution and purified water were obtained 
from our laboratory. All other chemicals and solvents 
used were of analytical grade. 
 
Equ ipment  
 
The analytical HPLC was performed on an chro-
matography system Agilent 1200 Series Diode Array 
and Multiple Wavelength detector (Agilent Technolo-
gies, USA). The HPLC system was controlled by the 
Agilent Chem Station software. The pH value was deter-
mined with a Microprocessor pH Meter (HANNA Instru-
ments, USA). For mixing the formulations, laboratory 
stirrer RW 16 basic (IKA® - Werke, Germany) was used. 
 
Formulat ions  
 
The clindamycin phosphate hydrophilic vaginal gels 
were formulated with three different mediums of gelation: 
Carbopol® 940, Carbopol® Ultrez 10 and Pe-mulen® TR 1 
(Table 1). In each of them, clindamycin phosphate is 
present with the same concentration - 2.4%. 
All of the three formulations were made using the 
same procedure, at room temperature. Disodium ede-
tate was dissolved in a certain volume of purified water 
(70 mL). Propylene glycol was added to an aqueous so-
lution of disodium edetate. The polymer was disperged 
in prepared solution. Dispersion was made by mixing 
with the laboratory stirrer at 700 r/m (in order to avoid 
the collapse of polymer gel structure, which results in 
the loss of viscosity of the Carbopol® gel) (13). The sodi- 
um hydroxide solution 10.0% (18 drops) (14) was added 
to the dispersion and mixed until the homogeneous gel 
was formed. 
Placebo of gel formulation containing all the nor-
mal ingredients like formulation F1, except clindamycin 
phosphate was also prepared for this study (Table 1). 
We used placebo of formulation F1 (with Carbopol® 940) 
because it is a recommended formulation for vaginal gel 
carrier in magistral practice (12). 
The samples were packed in plastic, tightly clo-
sed containers and kept in the dark at 20±5°C until 
analysis. 
 
Chromatographic  condi t ions 
 
The separation was achieved using a reverse pha-
se Zorbax Eclipse plus C8 column 1.8 μm, 50 mm× 
4.6 mm (Agilent Technologies, USA). 
The mobile phase involved acetonitrile and pH 
2.5 phosphate buffer (6.0±0.1 g of anhydrous sodium 
dihydrogenphosphate was dissolved in 1.0 L of deioni-
zed water, and adjusted to pH 2.5 with concentrated 
phosphoric acid) (15:85, v/v). Then, the mobile phase 
was filtered through a membrane filter 25/0.45 μm RC 
(Econofilter, Agilent Technologies, USA). As clindamy-
cin phosphate and its major degradant clindamycin can 
only be detected at low wavelenght (<220 nm), aceto-
nitrile (with low UV cut off) was chosen as organic mo-
difier for the mobile phase. The mobile phase flow rate 
was 1.0 mL/min. 
The injection volume was 10 μL and the column 
was maintained at 40°C. For quantification, clindamy-
cin phosphate was detected at 210 nm by UV/VIS de-
tector. The chromatogram was derived using the Agilent 
Chem Station software. 
 
Table 1. Formulations of clindamycin phosphate vaginal gels (F1, F2, F3) and placebo gel (P) 
F  o  r  m  u  l  a  t  i  o  n (g) 
Constituent 
F1 F2 F3 P 
Carbopol® 940 1.00 - - 1.00 
Carbopol® Ultrez 10 - 1.00 - - 
Pemulen® TR 1 - - 1.00 - 
Dinatrii edetas 0.10 0.10 0.10 0.10 
Propylenglycolum 10.00 10.00 10.00 10.00 
Natrii hydroxydi 
solutio 10% 
1.00 1.00 1.00 1.00 
Clindamicyni 
phosphas* 
2.40 2.40 2.40 - 
    Aqua purificata ad 100.00 100.00 100.00 100.00 
* equivalent to 2% clindamycin 
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Stock and work ing  standard  
so lut ions 
 
Clindamycin phosphate stock solution was pre-
pared by adding 10.0 mg clindamycin phosphate to a 
10.0 mL volumetric flask, dissolving this quantity in 
phosphate buffer solution (pH 2.5) and filling to the 
mark with the same solvent. The concentration of clin-
damycin phosphate in stock solution was 1000 μg mL-1. 
Working standard solutions were prepared by the di-
lution of the clindamycin phosphate stock solution with 
the same solvent to obtain five different concentrations 
within the range of interest, in this case, 10.0, 20.0, 
40.0, 60.0 and 80.0 μg mL-1. 
 
Preparat ion  of  sample  so lut ion  
 
The method was developed for the assay of three 
vaginal gel formulations prepared in our laboratory. All 
three formulations contained 2.4% clindamycin phos-
phate (equivalent to 2% clindamycin) as active drug in 
addition to a number of other formulation ingredients.
 An accurately weighed portion of gel contents 
equivalent to 0.60 mg of clindamycin phosphate (sam-
ple weight about 25 mg) was transferred to a 25 mL 
volumetric flask and dissolved in phosphate buffer so-
lution. After it, the flask was shaked vigorously, brought 
to the volume with the same solvent and filtered thro-
ugh membrane filter 25/0.45 μm RC (Econofilter, Agilent 
Technologies, USA). 
The same procedure was used for the prepara-
tion of all formulation samples (placebo - P, F1, F2 and 
F3). 
 
RESULTS AND DISCUSSION 
 
The determination of clindamycin phosphate in 
different vaginal gel formulations was achieved by an 
isocratic reverse phase HPLC. Isocratic conditions relate 
to the constant composition of mobile phase during the 
analysis (pH 2.5 phosphate buffer - eluent A and aceto-
nitrile - eluent B, 85:15, v/v). Clindamycine phosphate 
lacks a UV absorbing chromophore and can only be de-
tected in the low wavelenght UV range. 
The selectivity of assay was determined by pla-
cebo analysis. Placebo of gel formulation F1 containing 
all the normal ingredients except clindamycin phosphate 
was prepared for this study. It was treated in the same 
manner as other samples. The obtained chromatogram 
was used for the study of other ingredient interference 
on the selectivity of the clindamycin phosphate separa-
tion. The chromatograms obtained from samples of 
placebo P, clindamycin phosphate standard solution (at 
concentration of 100 ppm) and formulations F1, F2 and 
F3 are shown in Figures 2-4. 
Figures show that despite the presence of the 
peaks of pharmaceutical formulation base components 
on the obtained chromatograms, the peak of the clin-
damycin phosphate was properly separated from those 
ones. There was no interfering peak from placebo sam-
ple co-eluting with the clindamycin phosphate. 
A linearity relationship was evaluated across the 
range of analytical procedure. For the linearity experi-
ments, solutions of clindamycin phosphate were pre-
pared at five concentrations. The concentrations of 
clindamycin phosphate used were 10.0, 20.0, 40.0, 
60.0 and 80.0 μg mL-1. The calibration curve was con-
structed by analyzing the solutions of clindamycin pho-
sphate (Figure 5). The regression line was calculated 
as Y=A +BX, where X was the clindamycin phosphate 
concentration (μg mL-1) and Y was the response (peak 
area expressed as mAU*s). The regression data for clin-
damycin phosphate are presented in Table 2. 
Table 3 shows a set of typical system precision 
results from replicate injections of a standard solution 
of clindamycin phosphate 100 μg mL-1. The six repli-
cate injections gave relative standard deviations of less 
than 1.0% for the peak areas and retention times of 
this drug, demonstrating that the HPLC system was 
precise. 
Assay results obtained from chromatograms of 
clindamycin phosphate vaginal gel formulations (Table 
4) show that formulation with Carbopol® 940 has an 
optimal value for clindamycin phosphate concentration 
(difference between clindamycin phosphate added and 
clindamycin phosphate recovered is minimal). 
All formulations have recovery values that meet 
the criteria from the European Pharmacopoeia (the pre-
paration complies with the test if not more than one 
individual content is outside the limits of 85% to 115% 
of the average content and none is outside the limits of 
75% to 125% of the average content; Uniformity of 
mass of single-dose preparations - Test B) (15). In our 
case, only the content of the formulation F3 is outside 
the limits of 85% to 115% of the average content, but 
none is outside the limits of 75% to 125% of the ave-
rage content. 


































































































Figure 4. Chromatograms of clindamycin phosphate vaginal gel samples a) formulation F1,                               
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Figure 5. Calibration curve for clindamycin phosphate 
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Table 2. Linear regression data for clindamycin phosphate 
Parameter Clindamycin phosphate 
Concentration range (μg mL-1) 10 - 80 
Slope 0.0935 
Intercept 1.4488 




Table 3. HPLC system precision for peak areas and retention times 
of clindamycin phosphate from six replicate injections 




1 141.71 6.589 
2 142.28 6.588 
3 141.61 6.589 
4 141.79 6.589 
5 141.63 6.588 
6 142.69 6.590 
Average 141.95 6.589 




Table 4. Assay results from chromatograms of clindamycin phosphate vaginal gel formulations 













F1 (Carbopol® 940) 33.29 6.487 24.0 22.91±0.01 95.46±0.04 
F2 (Carbopol® Ultrez 
10) 
38.97 6.497 24.0 26.83±0.02 111.79±0.08 
F3 (Pemulen® TR 1) 41.96 6.529 24.0 28.90±0.015 120.42±0.06 
 





The described isocratic HPLC-UV method is sui-
table for the assay of clindamycin phosphate in the 
vaginal gel formulations and can be used to assess the 
chemical stability of the clindamycin phosphate in the 
formulations. It can be used for quality control and 
stability study samples analysis for vaginal gel formu-
lations. 
The method recovery was shown to be within 
75-125% with relative standard deviation of less than 
1.0% for clindamycin phosphate in the three different  
vaginal gel formulations. All formulations show stability 
during the analysis. 
Clindamycin phosphate concentration was diffe-
rent in vaginal gel formulations with different gelation 
agents. So, the conclusion is that gelation agents (gel 
carriers) have a significant influence on the clindamy-
cin phosphate concentration. 
The obtained results confirm that vaginal gel for-
mulation with Carbopol® 940 shows the maximal sta-
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Sa že tak  
 
Klindamicin je antibiotik efikasan protiv Gram-pozitivnih aeroba, kao i Gram-pozitivnih i Gram-nega-
tivnih anaerobnih patogena. Klindamicin (njegov fosfatni estar) korišćen je u ovoj studiji u cilju procene 
efikasnosti formulisanih vaginalnih gelova. 
 Cilj ove studije bio je da se razvije analitička metoda pogodna za određivanje klindamicin fosfata 
u različitim vaginalnim gelovima. Glavna razlika između formulacija gelova bila je u primeni različitih geli-
rajućih sredstava (Carbopol® 940, Carbopol® Ultrez 10 i Pemulen® TR 1). Nova izokratska HPLC metoda 
reverznih faza razvijena je u cilju određivanja klindamicin fosfata u ovim vaginalnim gelovima. Korišćena 
je Zorbax Eclipse plus C8 kolona. Mobilna faza se sastojala iz acetonitrila i fosfatnog pufera (pH=2,5), a 
UV detekcija je rađena na 210 nm. Uočen je linearan odgovor (r>0,99) u opsegu koncentracija klinda-
micin fosfata od 10,0-80,0 μg ml-1. Metoda pokazuje dobre vrednosti za Recovery, a vrednosti za rela-
tivnu standardnu devijaciju su manje od 1,0%. 
 Metoda može da se primeni u proceni stabilnosti vaginalnih gelova sa klindamicin fosfatom, za 
kontrolu kvaliteta preparata i u studijama stabilnosti uzoraka pri formulaciji vaginalnih gelova. 
 Koncentracija klindamicin fosfata je različita u formulacijama, pa se zaključuje da sredstvo za 
geliranje (podloga gela) ima značajan uticaj na koncentraciju aktivne supstance. Dobijeni rezultati po-
tvrđuju da vaginalni gel sa Carbopol-om (Carbopol® 940) pokazuje maksimalnu stabilnost tokom analize i 
obezbeđuje optimalnu koncentraciju klindamicin fosfata. 
 
Ključne reči: klindamicin fosfat; reverzno-fazna HPLC; vaginalni gel; Carbopol® 940 
 
 
 
  
 
 
 
 
 
 
 
 
 
